DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Encorafenib
Encorafenib
RP - HPLC Method Development & Validation for the Simultaneous Estimation of Encorafenib and Binimetinib in API & Tablet Dosage Form
FOI Reference: FOI 414 - 2021
Summary Risk Management Plan for Braftovi
New Century Health Policy Changes April 2021
The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era
Braftovi, INN-Encorafenib
In This Issue
Comparator Report on Cancer in Europe 2019 −Disease Burden, Costs and Access to Medicines
BRAF Gene and Melanoma: Back to the Future
BRAFTOVI (Encorafenib) RATIONALE for INCLUSION in PA PROGRAM
New Insights and Therapeutıc Implicatıons in Cutaneous Melanoma Pinar Ozuguz*, Serap Karatas and Seval Dogruk Kacar
Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted Therapy
Drug Consumption at Wholesale Prices in 2017 - 2020
Improvements in Clinical Outcomes for BRAFV600E-Mutant Colorectal Cancer
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
Kinase Drug Discovery 20 Years After Imatinib: Progress and Future Directions
Table 1: Drug-Drug Interactions of Common Cardiac Drugs and Chemotherapeutic Agents*
NCCN's Principles of Pathologic Review and Biomarker Testing
Top View
Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades
What's New in Immunotherapy and Targeted Therapy?
Treatment of Melanoma and Breast Cancer
A Validated LC–MS/MS Assay for the Simultaneous Quantification of the FDA-Approved Anticancer Mixture (Encorafenib and Binimet
Clinical Study ARRAY 818 302 Array Biopharma Inc
Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
Pharmacy Medical Necessity Guidelines: Oral Cancer Medications Effective: August 16, 2021
Rectal Cancer Treatment Regimens
Investor Presentation 1
NORVIR® Ritonavir (Ri-To-Na-Vir) Consumer Medicine Information (CMI)
Developments in the Space of New MAPK Pathway Inhibitors for BRAF-Mutant Melanoma
Numab Ono 2017
Intracranial Antitumor Activity with Encorafenib Plus Binimetinib in Patients with Melanoma Brain Metastases: a Case Series
Genomically Driven Tumors and Actionability Across Histologies: BRAF-Mutant Cancers As a Paradigm Michelle L
Binimetinib-Encorafenib
The NF1 Gene in Tumor Syndromes and Melanoma Maija Kiuru1 and Klaus J Busam2
Overview of Current Type I/II Kinase Inhibitors
ONO Receives Approval of BRAFTOVI® Capsule, a BRAF Inhibitor And
Adult Antiemetic Management of Chemotherapy-Induced Nausea
ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
Assessment of Vitamin D Levels in Newly Diagnosed Breast Cancer
Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors
Proton Pump Inhibitors and Oncologic Treatment Efficacy
Precision Medicine in Oncology: a Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer
Paradox Breaker BRAF Inhibitors Have Comparable Potency and MAPK Pathway Reactivation to Encorafenib in BRAF Mutant Colorectal Cancer
List of Cleared Or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools)
Pdf 10 Ascierto PA, Mcarthur GA, Dreno B, Et Al
Molecular Characterization of a Large Unselected Cohort of Metastatic Colorectal Cancers in Relation to Primary Tumor Location, Rare Metastatic Sites and Prognosis
ATC/DDD Classification (Temporary)
Resistance to Molecularly Targeted Therapies in Melanoma
Current Status of Biological Therapies for the Treatment of Metastatic Melanoma
Pharmacy & Therapeutics Committee Meeting
5.01.589 BRAF and MEK Inhibitors
Encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy
Encorafenib/Binimetinib Combination Therapy for Melanoma a Nursing Tool from the Melanoma Nursing Initiative (MNI)
Anti-Cancer Drugs Targeting Protein Kinases Approved by FDA in 2020
Diverse BRAF Gene Fusions Confer Resistance to EGFR-Targeted Therapy Via Differential Modulation of BRAF Activity Christina Stangl1,2, Jasmin B
FOI 138 – 2122 Title: Incidence and Treatment of Melanoma and Renal Cell Carcinoma Date: June 2021 FOI Category: Pharmacy
Emetic Risk of Single Intravenous Antineoplastic Agents in Adults
BRAFTOVI Safely and Effectively
Comparative Analysis of the Phototoxicity Induced by BRAF Inhibitors and Alleviation Through Antioxidants
Policy Drug(S)
Oncology Orals Solid Tumors
Real-World Experience with Targeted Therapy in BRAF Mutant Advanced
MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer
Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge On
Precision Oncology Drug Approvals in H1 2020 - New Drugs and Expanded Indications
Evidence Dossier
Could You Please Answer the Following Four Questions for Patients Treated by Your Trust?
16722836) Imatinib (Pubmed CID: 123596) in the Treatment of Urothelial Bladder Cancers
Current Development Status of MEK Inhibitors
Oncology Orals Medications
Colorectal and Gastric Cancer (Faculty Presentations)
409 Oncology Drugs
Braftovi and Mektovi
Precision Oncology Drug Approvals in 2020 - New Drugs and Expanded Indications
A New B-Raf Inhibitor Combo for Advanced Melanoma
Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma
Partner Only Release
MEDICATION GUIDE BRAFTOVI® (Braf-TOE-Vee) (Encorafenib) Capsules Important Information: BRAFTOVI Is Used with Other Medicines, Either Binimetinib Or Cetuximab
Colorectal and Gastric Cancer
Dose Recommendations for Anticancer Drugs in Patients with Renal Or Hepatic Impairment
Prior Authorization Criteria
Current Insights Into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade
Liste Der Oralen Antineoplastischen Wirkstoffe Stand: 29.06.2021